Tiziana Life Sciences Ltd SEC filings TLSA
Tiziana Life Sciences Ltd has 492 filings in SEC EDGAR's recent list, going back to Nov 30, 2017. Its latest annual report, Form 20-F, was filed on May 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 5, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Feb 20, 2026 | — |
| 424B5 | Prospectus supplement | Jan 22, 2026 | — |
| POS AM | Post-effective amendment no. 1 to form f-3 | Jan 21, 2026 | — |
| 424B5 | Prospectus supplement | Jan 16, 2026 | — |
| 424B5 | Prospectus supplement | Dec 12, 2025 | — |
| FWP | Free writing prospectus | Dec 12, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Mar 24, 2025 | — |
| 424B5 | Prospectus supplement | Nov 1, 2024 | — |
| 424B5 | Prospectus supplement | Oct 25, 2024 | — |
| 424B5 | Prospectus supplement | Sep 1, 2023 | — |
| F-3/A | Amendment no. 2 to form f-3 | Feb 25, 2022 | — |
| F-3/A | Amendment no. 1 to form f-3 | Feb 1, 2022 | — |
| F-3 | Shelf registration (foreign issuer) | Jan 26, 2021 | — |
| F-6 POS | Filing | Aug 27, 2020 | — |
| F-6EF | Filing | Aug 27, 2020 | — |
| 424B5 | Prospectus supplement | Aug 4, 2020 | — |
| F-6 POS | Filing | Jul 14, 2020 | — |
| 424B5 | Prospectus supplement | Apr 10, 2020 | — |
| 424B5 | Prospectus supplement | Mar 13, 2020 | — |
| FWP | Free writing prospectus | Feb 18, 2020 | — |
| FWP | Free writing prospectus | Feb 14, 2020 | — |
| 424B5 | Prospectus supplement | Feb 14, 2020 | — |
| F-3/A | Amendment no.1 to registration statement | Jan 30, 2020 | — |
| F-3 | Shelf registration (foreign issuer) | Jan 22, 2020 | — |
| F-6 POS | Filing | Oct 8, 2019 | — |
| FWP | Free writing prospectus | Sep 20, 2019 | — |
| F-1/A | Amendment no. 2 to form f-1/a | Sep 20, 2019 | — |
| F-1/A | Amendment no. 1 to form f-1 | Sep 17, 2019 | — |
| FWP | Free writing prospectus | Aug 6, 2019 | — |
| F-1 | Registration statement (foreign issuer) | Aug 5, 2019 | — |
| 424B4 | Prospectus | Nov 21, 2018 | — |
| POS AM | Post-effective amendment no. 1 to this registration statement | Nov 14, 2018 | — |
| F-1/A | Amendment no. 5 to registration statement | Oct 30, 2018 | — |
| F-6/A | Filing | Oct 29, 2018 | — |
| F-1/A | Amendment no. 4 to form f-1 | Oct 23, 2018 | — |
| F-1/A | Amendment no. 3 to form f-1 | Oct 18, 2018 | — |
| FWP | Free writing prospectus | Sep 25, 2018 | — |
| F-1/A | Amendment no. 2 to form f-1 | Sep 25, 2018 | — |
| F-6 | Filing | Sep 24, 2018 | — |
| F-1/A | Amendment no. 1 to form f-1 | Aug 23, 2018 | — |
| F-1 | Registration statement (foreign issuer) | Jul 26, 2018 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TLSA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Bermuda
- Headquarters
- London, England, United Kingdom
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1723069
- Former names
- Tiziana Life Sciences plc (until Oct 21, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.